Epidemiological characteristics, medical costs and healthcare resource utilization of diabetes-related complications among Chinese patients with type 2 diabetes mellitus

被引:17
作者
Duan, Xiaotuo [1 ]
Li, Yunguang [2 ]
Liu, Qingjing [3 ]
Liu, Li [4 ]
Li, Chaoyun [4 ]
机构
[1] Beijing Brainpower Pharma Consulting Co Ltd, Hlth Econ & Outcome Res, Beijing, Peoples R China
[2] Sanofi, Med Dept, Shanghai, Peoples R China
[3] Beijing North Med & Hlth Econ Res Ctr, Beijing, Peoples R China
[4] Sanofi, Hlth Econ & Outcome Res, 19F Tower 3,Kerry Ctr 1228,Middle Yanan Rd, Shanghai 200040, Peoples R China
关键词
Claims database; complications; direct medical cost; healthcare resource utilization; type 2 diabetes mellitus; COHORT;
D O I
10.1080/14737167.2019.1661777
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: To estimate the direct medical costs (DMCs) and healthcare resource utilization (HRU) of type 2 diabetes mellitus (T2DM)-related complications in China. Methods: Data from a total of 74,507 patients were extracted from the 2015 China Health Insurance Research Association Claims Database. The complications determined by primary diagnoses were categorized into three groups: 1) for mild acute and local chronic complications, both outpatients and inpatients were considered; 2) for severe acute complications, only inpatiens were considered; 3) for systemic chronic complications, a 1:1 propensity-score matching was performed to calculate the incremental DMCs and HRU of preexisting and new-onset patients. Results: Among the mild acute and local chronic complications, the DMCs and HRU per event were the highest for gangrene and laser treatment. Of the severe acute complications, the DMCs and HRU per event were highest for hyperosmotic nonketonic diabetic coma (HNDC), followed by severe hypoglycemia and ketosis. For systemic chronic complications, the DMCs and HRU associated with dialysis and myocardial infarction were the highest both in patients with new-onset complications and preexisting complications. Conclusions: The estimated economic data are required for policy decisions to optimize resource allocation and to evaluate different approaches for disease management.
引用
收藏
页码:513 / 521
页数:9
相关论文
共 27 条
[1]   Incorporation of suboptimal health status as a potential risk assessment for type II diabetes mellitus: a case-control study in a Ghanaian population [J].
Adua, Eric ;
Roberts, Peter ;
Wang, Wei .
EPMA JOURNAL, 2017, 8 (04) :345-355
[2]   Impaired wound healing: facts and hypotheses for multi-professional considerations in predictive, preventive and personalised medicine [J].
Avishai, Eden ;
Yeghiazaryan, Kristina ;
Golubnitschaja, Olga .
EPMA JOURNAL, 2017, 8 (01) :23-33
[3]   Direct cost of patients with type 2 diabetes mellitus healthcare and its complications in Lithuania [J].
Domeikiene, Aukse ;
Vaivadaite, Justina ;
Ivanauskiene, Rugile ;
Padaiga, Zilvinas .
MEDICINA-LITHUANIA, 2014, 50 (01) :54-60
[4]   Diabetes care in figures: current pitfalls and future scenario [J].
Duarte, Alexandre Assuane ;
Mohsin, Shahriar ;
Golubnitschaja, Olga .
EPMA JOURNAL, 2018, 9 (02) :125-131
[5]   Suboptimal health status as an independent risk factor for type 2 diabetes mellitus in a community-based cohort: the China suboptimal health cohort study [J].
Ge, Siqi ;
Xu, Xizhu ;
Zhang, Jie ;
Hou, Haifeng ;
Wang, Hao ;
Liu, Di ;
Zhang, Xiaoyu ;
Song, Manshu ;
Li, Dong ;
Zhou, Yong ;
Wang, Youxin ;
Wang, Wei .
EPMA JOURNAL, 2019, 10 (01) :65-72
[6]   Estimating the Cost of Diabetes Mellitus-Related Events from Inpatient Admissions in Sweden Using Administrative Hospitalization Data [J].
Gerdtham, Ulf-G ;
Clarke, Philip ;
Hayes, Alison ;
Gudbjornsdottir, Soffia .
PHARMACOECONOMICS, 2009, 27 (01) :81-90
[7]   Global estimates of diabetes prevalence for 2013 and projections for 2035 [J].
Guariguata, L. ;
Whiting, D. R. ;
Hambleton, I. ;
Beagley, J. ;
Linnenkamp, U. ;
Shaw, J. E. .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 103 (02) :137-149
[8]  
[贺明娟 He Mingjuan], 2014, [中国糖尿病杂志, Chinese Journal of Diabetes], V22, P452
[9]   Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review [J].
Hong, Dongzhe ;
Si, Lei ;
Jiang, Minghuan ;
Shao, Hui ;
Ming, Wai-kit ;
Zhao, Yingnan ;
Li, Yan ;
Shi, Lizheng .
PHARMACOECONOMICS, 2019, 37 (06) :777-818
[10]   Economic Burden in Chinese Patients with Diabetes Mellitus Using Electronic Insurance Claims Data [J].
Huang, Yunyu ;
Vemer, Pepijn ;
Zhu, Jingjing ;
Postma, Maarten J. ;
Chen, Wen .
PLOS ONE, 2016, 11 (08)